Abstract
To evaluate the role of sex in nevirapine pharmacokinetics, we analysed the pharmacokinetic profile of nevirapine in 11 male and 11 female HIV-positive patients chronically treated with nevirapine 400 mg once a day. Statistically significant inter-group differences in the plasma concentration and fluctuations between that and the concentration just before the next dose, at steady-state, were observed. Variations in lean body mass and composition affecting nevirapine distribution might account for inter-sex discrepancies in nevirapine plasma levels.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
